Sanofi Raises Full-Year Outlook Amid Strong Q2 Performance Driven by Dupixent Growth
Sanofi reported a strong second-quarter performance with sales rising 17.8% to €11.6 billion and business EPS increasing 33.3%, driven primarily by the success of its blockbuster drug, Dupixent. The company raised its full-year outlook for both revenue and earnings per share growth due to robust demand across key products and cost discipline. Dupixent sales exceeded €5 billion in Q2, up 37% year-over-year, prompting Sanofi to increase its long-term sales ambition for the drug from approximately €18.6 billion to around €25 billion by 2030. Growth was supported by new indications and a global patient base now exceeding 1.5 million. Despite strong performance in pharmaceutical launches and rare diseases, vaccines saw a 5% decline year-over-year. Sanofi also announced strategic changes within its pipeline, including the discontinuation of several programs to focus on more promising opportunities.
Tickers: $SNY
Topics: dupixent financial_performance pharmaceuticals pipeline_review